EIKN — Eikon Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1861123 ·
Last close
$7.92
Market Cap
$428.99M
52W High
$17.40
52W Low
$7.72
ADV30
630,603
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -93,394,000 | -88,409,000 | 779,570,000 | 142,613,000 | 313,070,000 |
| Mar 2026 | 0 | — | -87,337,000 | -82,958,000 | 850,826,000 | 161,154,000 | 300,155,000 |
| Dec 2025 | 0 | — | -83,168,000 | -79,655,000 | 594,734,000 | 104,901,000 | 1,473,768,000 |
| Sep 2025 | — | — | — | — | 642,337,000 | 104,868,000 | 1,446,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-209,786,000
Investing CF
$-368,208,000
Financing CF
$700,726,000
CapEx
$-62,204,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.74
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,003,467,000
Inventory
—
Receivables
—
ST Investments
$351,028,000
EBIT TTM
$-303,340,000
Pretax Income TTM
$-295,780,000
Interest Exp TTM
$-41,000
Analysts
4
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -338,945,000 | -324,248,000 | 594,734,000 | 1,473,768,000 | -879,034,000 | -188,516,000 |
| Dec 2024 | 0 | -260,343,000 | -243,814,000 | 491,240,000 | 1,063,170,000 | -571,930,000 | -134,799,000 |
| Dec 2023 | 0 | -265,737,000 | -241,997,000 | 525,705,000 | 867,078,000 | -341,373,000 | -190,848,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.33
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc. | $421.15M | $6.81 | — |
| TECX | Tectonic Therapeutic, Inc. | $462.73M | $23.67 | — |
| EDIT | Editas Medicine, Inc. | $396.24M | $2.58 | — |
| ENTX | Entera Bio Ltd. | $475.27M | $2.74 | — |
| ZURA | Zura Bio Ltd | $387.15M | $4.04 | — |
News headlines (Yahoo Finance, 1h cache)
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
2026-09-03 11:30 · Yahoo
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
2026-08-22 11:01 · Yahoo
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
2026-08-18 20:15 · Yahoo
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
2026-08-11 11:30 · Yahoo
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
2026-07-27 11:30 · Yahoo
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
2026-07-20 12:00 · Yahoo
Eikon Therapeutics to Join the Russell 3000® Index
2026-06-25 20:15 · Yahoo
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
2026-06-08 12:00 · Yahoo
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
2026-05-21 21:05 · Yahoo
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
2026-05-11 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.